基石药业（苏州）有限公司 CSTONE PHARMACEUTICALS
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
CStone Pharmaceuticals Announces Updated Results from Two Studies of Its Anti-PD-L1 Monoclonal Antibody Sugemalimab (CS1001) At 2020 CSCO Annual Meeting 2020-09-25 15:28
CStone Announces Preliminary Results from a Bridging Study of Avapritinib in Chinese Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors at the 2020 CSCO Annual Meeting 2020-09-25 14:53
CStone Receives US FDA IND Clearance for CS1001-201 Study to Evaluate Anti-PD-L1 Monoclonal Antibody Sugemalimab Monotherapy in R/R ENKTL 2020-08-31 11:35
CStone Pharmaceuticals Reports Financial Results for the First Half of 2020 2020-08-19 09:33
CStone submits new drug application for the targeted therapy avapritinib in Taiwan for the treatment of adults with advanced PDGFRA exon 18 mutant gastrointestinal stromal tumor 2020-03-27 14:02
CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib 2020-01-24 14:26
CStone successfully hosted the first U.S. R&D Day in New York 2020-01-24 08:18
CStone successfully hosted the first U.S. R&D Day in New York 2020-01-24 08:03
CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma 2020-01-08 13:45
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia 2019-12-12 14:47
CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST 2019-12-11 11:00
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma 2019-12-10 11:38
CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial 2019-12-06 18:53
CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib 2019-11-20 11:41
ASH 2019 | CStone's anti-PD-L1 antibody demonstrates a complete response rate of 31.8% in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma 2019-11-07 11:02
ESMO 2019: CStone presents pooled safety data from the Phase 1b trial of CS1001, demonstrating promising overall safety and tolerability 2019-09-30 18:29
2019 CSCO| CStone announces promising ORR, anti-tumor activity and safety data with its anti-PD-L1 antibody CS1001 in MSI-H/dMMR solid tumors 2019-09-22 14:22
2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab 2019-09-22 13:39
2019 CSCO | CStone releases preliminary results from the Phase Ia trial of CS1003 in Chinese patients with advanced tumors 2019-09-21 00:26
2019 CSCO | CStone announces promising trial data on its anti-PD-L1 antibody in esophageal squamous cell carcinoma with an ORR of 77.8% 2019-09-19 23:48
1 3 4 5 6 7 8